Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$3.10 -2.2%	$2.76	$1.14 ▼ $4.08	$428.67M	1.49	1.42 million shs	7.37 million shs
CURR Currenc Group	$1.38 +3.0%	$1.23	$0.33 ▼ $12.39	$64.21M	-0.13	3.94 million shs	281,008 shs
SLRN Acelyrin	$2.27	$2.27	$1.85 ▼ $7.10	$229.17M	1.07	1.29 million shs	N/A
TSVT 2seventy bio	$5.00	$5.00	$2.29 ▼ $5.30	$266.15M	1.04	650,169 shs	N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-5.09%	+8.19%	+17.41%	+58.50%	+180.53%
CURR Currenc Group	-12.42%	-23.86%	-14.65%	+34.00%	+133,999,900.00%
SLRN Acelyrin	0.00%	0.00%	0.00%	+10.73%	-50.22%
TSVT 2seventy bio	0.00%	0.00%	0.00%	0.00%	+18.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.8793 of 5 stars	3.6	1.0	2.8	5.0	0.0
CURR Currenc Group	2.3818 of 5 stars	3.8	0.0	2.2	2.5	0.0
SLRN Acelyrin	2.1024 of 5 stars	3.2	0.0	0.6	2.5	1.3
TSVT 2seventy bio	0.3374 of 5 stars	1.0	0.0	0.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.89	315.77% Upside
CURR Currenc Group	3.50	Strong Buy	$3.50	153.62% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
TSVT 2seventy bio	2.00	Hold	$5.00	N/A

Current Analyst Ratings Breakdown

Latest CURR, TSVT, CMPX, and SLRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	504.32	N/A	N/A	$0.91 per share	3.41
CURR Currenc Group	$46.44M	1.38	N/A	N/A	($0.71) per share	-1.94
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
TSVT 2seventy bio	$48.37M	5.50	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-49.76%	-44.20%	N/A
CURR Currenc Group	-$39.47M	-$1.06	N/A	∞	N/A	-102.10%	N/A	-39.14%	8/19/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	N/A
TSVT 2seventy bio	-$217.57M	-$0.10	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	N/A

Latest CURR, TSVT, CMPX, and SLRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	CURR Currenc Group	-$0.04	N/A	N/A	N/A	$10.40 million	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/4/2025	Q2 2025	CURR Currenc Group	-$0.04	-$0.10	-$0.06	-$0.10	$10.40 million	$8.71 million
5/20/2025	Q1 2025	CURR Currenc Group	-$0.04	-$0.13	-$0.09	-$0.13	$10.50 million	$10.06 million
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CURR Currenc Group	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
CURR Currenc Group	N/A	0.62	0.62
SLRN Acelyrin	N/A	7.15	7.15
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CURR Currenc Group	56.01%
SLRN Acelyrin	87.31%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CURR Currenc Group	43.30%
SLRN Acelyrin	13.60%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CURR Currenc Group	2	46.53 million	26.38 million	N/A
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
TSVT 2seventy bio	440	53.23 million	47.87 million	Optionable

CURR, TSVT, CMPX, and SLRN Headlines

Recent News About These Companies

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

May 7, 2025 | businesswire.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

March 12, 2025 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

March 11, 2025 | businesswire.com

2seventy bio accepts Bristol Myers’ takeover bid

March 11, 2025 | thepharmaletter.comT

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

March 11, 2025 | investorideas.comI

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

March 11, 2025 | tmcnet.com

2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

March 11, 2025 | markets.businessinsider.com

TSVT Up on Acquisition Agreement With BMY for $286 Million

March 11, 2025 | zacks.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

March 11, 2025 | prnewswire.com

Bristol Myers buys out cell therapy partner 2seventy bio

March 11, 2025 | endpts.comE

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

March 10, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CURR, TSVT, CMPX, and SLRN Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$3.10 -0.07 (-2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$3.11 +0.01 (+0.32%)

As of 05:25 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Currenc Group NASDAQ:CURR

$1.38 +0.04 (+2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 05:37 PM Eastern

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

2seventy bio NASDAQ:TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time